Pharmaceutical import and export volume in the first quarter of 2017 $25.6 billion

Source: Sina Pharmaceutical News 2017-05-09 according to the latest data released by China Chamber of Commerce for the import and export of medical and health products, in the first quarter of 2017, the export volume of medical and health products in China was 13.4 billion US dollars, up 2% year-on-year, and the import volume was 12.2 billion US dollars, up 15.5% In the first quarter of this year, the "counter attack" of export API showed a positive growth, taking the VC price of China as an example, from $4 per kilogram to a maximum of $10; in addition, the export of preparations also kept rising, up 11% year on year However, China's export of plant extracts continued to fall sharply, down about 12% year on year In general, China's import and export of medical and health products started well in the first quarter of 2017 According to the research and forecast conducted by China Chamber of Commerce for import and export of pharmaceutical and health care products, the development of pharmaceutical export and import will be better this year than in 2016 Xu Ming, vice president of China Chamber of Commerce for the import and export of healthcare products, said that the development of China's pharmaceutical industry is in a node of rapid upgrading and major changes are about to take place At the government level, the drug regulatory authorities accelerated the review, and the health system further deepened the reform of the medical system; at the industrial development level, the international pace was accelerated, the quality level was improved, and the implementation of the two vote system for drug circulation accelerated the merger and reorganization of the whole industry, greatly improving the efficiency Especially last year, the state issued a series of policies to support the development of the pharmaceutical industry, such as the outline of "healthy China 2030" plan, which shows that the health industry has been highly concerned by the government and ordinary people Without the development of the pharmaceutical industry, it will be difficult to achieve China's two centenary goals At such a historical stage, the pharmaceutical industry will be accelerated In the first quarter of this year, the export volume of preparations showed a steady upward trend, reaching US $77000000, up 10.9% year on year Traditional antibiotic drugs, vitamin drugs, hormone drugs and insulin drugs have achieved a significant increase From the perspective of market, China's pharmaceutical exports to the EU, the United States, ASEAN and other markets have increased significantly, with a year-on-year growth of 71%, 25% and 15%, respectively, but the exports to South America and South Korea have declined significantly On the whole, domestic pharmaceutical enterprises are increasingly diversified in their participation in international division of labor Green leaf, humanwell, Huahai and Fosun have successively acquired European and American and Indian enterprises, expanded production lines of generic drugs, and Hengrui, Zhengda Tianqing and Shiyao are authorized to multinational enterprises for their products under research In addition, the pace of R & D and international listing of enterprises has been further accelerated, and companies such as Ted and Sinopharm have increased their efforts to expand the Japanese market In the future, the export of Chinese preparations to the markets of developed countries is expected to accelerate However, it is difficult for China's export growth of Western pharmaceutical preparations to increase significantly in 2017, for the following reasons: first, in the international aspect, the world economy is still facing many uncertainties Trump came to power in the United States to abolish Obama's health care reform, plan to reform the drug review and biomedical fields, brexit in the UK, referendum in Italy, slow economic recovery in Europe, political influence on economic development in Japan and South Korea, falling commodity prices in emerging economies in Africa and South America, and further decline in payment capacity due to tight financial conditions, all of which have brought certain uncertainties to our pharmaceutical exports Certainty Secondly, with the implementation of consistency evaluation and two vote system, Chinese pharmaceutical industry will enter a new round of adjustment period Although the overall pharmaceutical market will continue to expand and the import and export will maintain a relatively stable growth, the opportunity for a substantial increase in exports is still not ripe In the first quarter of 2017, with the overall recovery of China's foreign trade, China's API trade also showed a good momentum of steady growth, with the import and export volume reaching 8.882 billion US dollars, up 9.6% year-on-year Among them, the export volume was US $6.722 billion, an increase of 6.71% year-on-year, but the trend of volume increase and price decrease since 2016 was continued While the export volume increased by 14.21%, the average export price fell by 6.57% Amino acids, penicillins, hormones, cephalosporins and other bulk APIs are still the main categories for price reduction and promotion However, the average export price of antipyretics and analgesics rebounded, and the price of vitamins continued to rise The export of APIs to the markets of all continents was positive growth In terms of countries, exports to the United States and South Korea increased by more than 20% year-on-year; imports reached US $2.16 billion, an increase of 19.69% year-on-year, which also showed a trend of increase in volume and decrease in price While the export volume increased by 25.49%, the average export price fell by 4.62% The first quarter has created a good start for the whole year's API trade, and it is expected to continue to maintain positive growth in the second quarter To improve innovation and competition, internationalization of pharmaceutical enterprises is an inevitable trend Over the past three decades of reform and opening up, the development of APIs has ushered in many market opportunities, but many opportunities have come along with the trend The development of APIs in China caters to the rising period of the development of the world's pharmaceutical industry, especially in the past 20 years, China has seized this opportunity period, many of which benefits are based on China's comparative advantages in cost, environment and so on, at the same time, it has paid a great price Generally speaking, Xu Ming believes, China is the winner But the next step should be the core stage for Chinese enterprises to change from comparative advantage to competitive advantage, which is embodied in the combination of various competitive advantages, and more depends on the strength of enterprises themselves At present, the competitive advantages of domestic pharmaceutical enterprises can not meet the needs of the industry for quite some time now and in the future At present, Chinese pharmaceutical enterprises are facing two dimensions of competition The first is the competition of time The State Food and drug administration has vigorously accelerated the speed of evaluation CDE staff has now increased by more than 600 The current "China new" and "global new" are racing against time If Chinese Enterprises do not start from the core competitiveness, they will be defeated by foreign-funded enterprises at the door of the country The second is the race of space Many Chinese pharmaceutical enterprises have entered the United States, Australia and Europe to apply for new drug trials (ind) At present, there are more than 70 Chinese enterprises applying for ind in the United States, such as Baiji Shenzhou, Hengrui medicine, dongyangyao, Yasheng medicine, etc., which makes the clinical trial results can achieve international synchronization, and the geographical concept has no impact In this case, if Chinese pharmaceutical companies want to really turn "China new" into "global new", they can only highlight their innovation advantages and win the competition by jointly improving speed in the two dimensions of time and space At the same time, Xu Ming stressed that the internationalization of the pharmaceutical industry will become an inevitable trend in the future At present, the link between Chinese enterprises and the world is still more at the level of trade, but the next step, with the extension of the industry supply chain, leading to the extension of the industry chain, the development of Chinese medicine in the future is bound to find its own position in the large production system, is the overall "seamless" integration of the Chinese pharmaceutical industry chain and the global industry chain In the process of entering the international market, Chinese enterprises need to solve the following problems: first, registration and certification At present, there are more than 70 enterprises in China that have passed the GMP certification in Europe and the United States, 18 preparations, 32 APIs and 3 vaccines have passed the PQ, and their international strength is relatively weak Registration and certification is the first obstacle for Chinese pharmaceutical enterprises to enter the international market Secondly, market access If Chinese enterprises want to pass EMA, they need to establish branches in European countries, or cooperate with local distributors However, the policies and actual situation of each European country are different, which requires enterprises to deal with them separately according to their national conditions In addition, the internationalization of Chinese enterprises will face a series of problems, such as the pricing of products in the process of entering the local medical insurance system, the handling of pharmacovigilance after listing, the response of the media and drug regulatory officials brought by pharmacovigilance, and the recall of drugs In 2016, Fosun Pharmaceutical's US $1.26 billion acquisition of gland Pharma was a major move in the Chinese pharmaceutical industry In the future, more and more Chinese pharmaceutical enterprises may choose to acquire foreign enterprises to improve their core competitiveness in a short period of time through merger and reorganization.